Patents by Inventor Erol K. Bayburt

Erol K. Bayburt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRPV3 modulators
    Patent number: 9156788
    Abstract: Disclosed herein are modulators of TRPV3 of formula (I) wherein G1, X1, X2, X3, X4, X5, G2, Z1, Ra, Rb, u, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: October 13, 2015
    Assignee: AbbVie Inc.
    Inventors: Erol K. Bayburt, Bruce Clapham, Phil B. Cox, Jerome F. Daanen, Arthur Gomtsyan, Michael E. Kort, Philip R. Kym, Eric A. Voight
  • TRPV3 modulators
    Patent number: 8772500
    Abstract: Disclosed herein are modulators of TRPV3 of formula (II): wherein G1, X1, X2, X3, X4, X5, G2, Ra, Rb, and u are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
    Type: Grant
    Filed: October 23, 2012
    Date of Patent: July 8, 2014
    Assignee: AbbVie Inc.
    Inventors: Erol K. Bayburt, Bruce Clapham, Phil B. Cox, Jerome F. Daanen, Michael J. Dart, Gregory A. Gfesser, Arthur Gomtsyan, Michael E. Kort, Philip R. Kym, Robert G. Schmidt
  • TRPV3 modulators
    Patent number: 8772499
    Abstract: Disclosed herein are modulators of TRPV3 of Formula (I) wherein p is 1, 2, 3, or 4, and G1, X1, X2, X3, X4, X5, G2, Z1, Ra, Rb, and u are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
    Type: Grant
    Filed: October 23, 2012
    Date of Patent: July 8, 2014
    Assignee: AbbVie Inc.
    Inventors: Erol K. Bayburt, Bruce Clapham, Phil B. Cox, Jerome F. Daanen, Michael J. Dart, Gregory A. Gfesser, Arthur Gomtsyan, Michael E. Kort, Philip R. Kym, Robert G. Schmidt, Eric A. Voight
  • NOVEL TRPV3 MODULATORS
    Publication number: 20140080803
    Abstract: Disclosed herein are modulators of TRPV3 of Formula (I) wherein p is 1, 2, 3, or 4, and G1, X1, X2, X3, X4, X5, G2, Z1, Ra, Rb, and u are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
    Type: Application
    Filed: October 23, 2012
    Publication date: March 20, 2014
    Applicant: AbbVie Inc.
    Inventors: Erol K. Bayburt, Bruce Clapham, Phil B. Cox, Jerome F. Daanen, Michael J. Dart, Gregory A. Gfesser, Arthur Gomtsyan, Michael E. Kort, Philip R. Kym, Robert G. Schmidt, Eric A. Voight
  • TRPV1 antagonists
    Patent number: 8609692
    Abstract: Disclosed herein are compounds of formula (I), or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Grant
    Filed: October 15, 2009
    Date of Patent: December 17, 2013
    Assignee: AbbVie Inc.
    Inventors: Arthur R. Gomtsyan, Erol K. Bayburt, Jun Chen, Stanley DiDomenico, Jerome F. Daanen, Michael E. Kort, Philip R. Kym, Heath A. McDonald, Richard J. Perner, Robert G. Schmidt, Eric A. Voight
  • TRPV1 antagonists
    Patent number: 8604053
    Abstract: Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Grant
    Filed: October 15, 2009
    Date of Patent: December 10, 2013
    Assignee: AbbVie Inc.
    Inventors: Arthur R. Gomtsyan, Eric A. Voight, Erol K. Bayburt, Jun Chen, Jerome F. Daanen, Stanley DiDomenico, Michael E. Kort, Philip R. Kym, Heath A. McDonald, Richard J. Perner, Robert G. Schmidt
  • Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
    Patent number: 8487116
    Abstract: The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X1-X5, R5-R8b, Z1-Z2 and Ar1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.
    Type: Grant
    Filed: November 9, 2011
    Date of Patent: July 16, 2013
    Assignee: AbbVie Inc.
    Inventors: Arthur R. Gomtsyan, Erol K. Bayburt, John R. Koenig, Chih-Hung Lee, Robert G. Schmidt, Kirill A. Lukin, Gilles Chambournier, Margaret Chi-Ping Hsu, Robert M. Leanna, Russell D. Cink
  • Tetrahydroquinolinyl compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof
    Patent number: 8440691
    Abstract: Compounds that are antagonists of the VR1 receptor, having formula (I) or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A1, A2, A3, A4, R7, R8, R9, X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.
    Type: Grant
    Filed: September 3, 2010
    Date of Patent: May 14, 2013
    Assignee: AbbVie Inc.
    Inventors: Arthur Gomtsyan, Erol K. Bayburt, Robert G. Schmidt, Jr., Chih-Hung Lee, Brian S. Brown, Tammie K. Jinkerson, John R. Koenig, Jerome F. Daanen, Steven P. Latshaw
  • Antagonists of the TRPV1 receptor and uses thereof
    Patent number: 8350083
    Abstract: The present application is directed to compounds that are TRPV1 antagonists and have formula (I) wherein variables Ar1, L1, R1, R2, R3, R4, R5, Y1, Y2, and Y3, are as defined in the description, which are useful for treating disorders caused by or exacerbated by vanilloid receptor activity.
    Type: Grant
    Filed: September 29, 2011
    Date of Patent: January 8, 2013
    Assignee: AbbVie Inc.
    Inventors: Arthur R. Gomtsyan, Robert G. Schmidt, Jerome F. Daanen, Erol K. Bayburt, Chih-hung Lee, Steven P. Latshaw
  • TRPV1 antagonists
    Patent number: 8338603
    Abstract: The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4, R5, m, and n are defined in the specification are TRPV1 antagonists. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Grant
    Filed: December 27, 2011
    Date of Patent: December 25, 2012
    Assignee: AbbVie Inc.
    Inventors: Arthur R. Gomtsyan, Robert G. Schmidt, Erol K. Bayburt, Jerome F. Daanen, Michael E. Kort
  • PRODRUGS OF COMPOUNDS THAT INHIBIT TRPV1 RECEPTOR
    Publication number: 20120277190
    Abstract: Compounds of formula (I) wherein A, R1, R2, and R3 are defined in the specification, and which are useful as therapeutic compounds particularly for treating disorders or conditions associated with inflammation, pain, bladder overactivity, urinary incontinence, and other disorders caused by or exacerbated by TRPV1.
    Type: Application
    Filed: July 9, 2012
    Publication date: November 1, 2012
    Inventors: Arthur R. Gomtsyan, Erol K. Bayburt, John R. Koenig, Kennan C. Marsh, Robert G. Schmidt, JR., Chih-Hung Lee, Weili Wang, Jerome F. Daanen, Brian S. Brown
  • Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
    Patent number: 8247413
    Abstract: Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity, wherein X1, X2, X3, X4, X5, R5, R6, R7, R8a, R8b, R9, Z1, Z2 and L are as defined in the description.
    Type: Grant
    Filed: February 19, 2008
    Date of Patent: August 21, 2012
    Assignee: Abbott Laboratories
    Inventors: Chih-Hung Lee, Erol K. Bayburt, Stanley Didomenico, Jr., Irene Drizin, Arthur R. Gomtsyan, John R. Koenig, Richard J. Perner, Robert G. Schmidt, Jr., Sean C. Turner, Tammie K. White, Guo Zhu Zheng
  • Prodrugs of compounds that inhibit TRPV1 receptor
    Patent number: 8232309
    Abstract: Compounds of formula (I) wherein A, R1, R2, and R3 are defined in the specification, and which are useful as therapeutic compounds particularly for treating disorders or conditions associated with inflammation, pain, bladder overactivity, urinary incontinence, and other disorders caused by or exacerbated by TRPV1.
    Type: Grant
    Filed: October 27, 2006
    Date of Patent: July 31, 2012
    Assignee: Abbott Laboratories
    Inventors: Arthur R. Gomtsyan, Erol K. Bayburt, John R. Koenig, Kennan C. Marsh, Robert G. Schmidt, Jr., Chih-Hung Lee, Weili Wang, Jerome F. Daanen, Brian S. Brown
  • FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR
    Publication number: 20120190845
    Abstract: The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X1-X5, R5-R8b, Z1-Z2 and Ar1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.
    Type: Application
    Filed: November 9, 2011
    Publication date: July 26, 2012
    Inventors: Arthur R. Gomtsyan, Erol K. Bayburt, Chih-Hung Lee, John R. Koenig, Robert G. Schmidt, Kirill A. Lukin, Gilles Chamboumier, Margaret Chi-Ping Hsu, Robert M. Leanna, Russell D. Cink
  • TRPV1 ANTAGONISTS
    Publication number: 20120108642
    Abstract: The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4, R5, m, and n are defined in the specification are TRPV1 antagonists. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Application
    Filed: December 27, 2011
    Publication date: May 3, 2012
    Inventors: Arthur R. Gomtsyan, Robert G. Schmidt, Erol K. Bayburt, Jerome F. Daanen, Michael E. Kort
  • ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF
    Publication number: 20120022103
    Abstract: The present application is directed to compounds that are TRPV1 antagonists and have formula (I) wherein variables Ar1, L1, R1, R2, R3, R4, R5, Y1, Y2, and Y3, are as defined in the description, which are useful for treating disorders caused by or exacerbated by vanilloid receptor activity.
    Type: Application
    Filed: September 29, 2011
    Publication date: January 26, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Erol K. Bayburt, Jerome F. Daanen, Arthur R. Gomtsyan, Steven P. Latshaw, Chih-hung Lee, Robert G. Schmidt, JR.
  • TRPV1 antagonists
    Patent number: 8084616
    Abstract: The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4, R5, m, and n are defined in the specification are TRPV1 antagonists. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Grant
    Filed: October 23, 2008
    Date of Patent: December 27, 2011
    Assignee: Abbott Laboratories
    Inventors: Arthur R. Gomtsyan, Robert G. Schmidt, Erol K. Bayburt, Jerome F. Daanen, Michael E. Kort
  • Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
    Patent number: 8071762
    Abstract: The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X1-X5, R5-R8b, Z1-Z2 and Ar1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.
    Type: Grant
    Filed: April 30, 2008
    Date of Patent: December 6, 2011
    Assignee: Abbott Laboratories
    Inventors: Arthur R. Gomtsyan, Erol K. Bayburt, Chih-Hung Lee, John R. Koenig, Robert G. Schmidt, Kirill A. Lukin, Gilles Chambournier, Margaret Chi-Ping Hsu, Marvin R. Leanna, Russell D. Cink
  • Antagonists of the TRPV1 receptor and uses thereof
    Patent number: 8030504
    Abstract: The present application is directed to compounds that are TRPV1 antagonists and have formula (I) wherein variables Ar1, L1, R1, R2, R3, R4, R5, Y1, Y2, and Y3, are as defined in the description, which are useful for treating disorders caused by or exacerbated by vanilloid receptor activity.
    Type: Grant
    Filed: December 12, 2007
    Date of Patent: October 4, 2011
    Assignee: Abbott Laboratories
    Inventors: Erol K. Bayburt, Jerome F. Daanen, Arthur R. Gomtsyan, Steven P. Latshaw, Chih-hung Lee, Robert G. Schmidt, Jr.
  • Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
    Patent number: 8026256
    Abstract: Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence, or bladder overactivity.
    Type: Grant
    Filed: October 26, 2005
    Date of Patent: September 27, 2011
    Assignee: Abbott Laboratories
    Inventors: Arthur Gomtsyan, Erol K. Bayburt, John R. Koenig, Chih-Hung Lee